Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 15, 2014, 114 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $538.00 to $2,081,081.25.

Highlighted Stocks Traded by Insiders:

MKS Instruments (MKSI) - FREE Research Report

Quirk Brian Charles, who is Sr. VP, Global Operations at MKS Instruments, sold 1,041 shares at $35.97 on Dec. 15, 2014. Following this transaction, the Sr. VP, Global Operations owned 3,122 shares meaning that the stake was reduced by 25.01% with the 1,041-share transaction.

The shares most recently traded at $35.60, down $0.37, or 1.04% since the insider transaction. Historical insider transactions for MKS Instruments go as follows:

  • 4-Week # shares bought: 1,161
  • 4-Week # shares sold: 4,385
  • 12-Week # shares bought: 1,161
  • 12-Week # shares sold: 18,999
  • 24-Week # shares bought: 1,161
  • 24-Week # shares sold: 38,499

The average volume for MKS Instruments has been 292,800 shares per day over the past 30 days. MKS Instruments has a market cap of $1.9 billion and is part of the technology sector and electronics industry. Shares are up 20.72% year-to-date as of the close of trading on Friday.

MKS Instruments, Inc. operates as a provider of instruments, subsystems, and process control solutions that measure, control, power, monitor, and analyze critical parameters of manufacturing processes in the United States and internationally. The stock currently has a dividend yield of 1.81%. The company has a P/E ratio of 19.2. Currently, there are 4 analysts who rate MKS Instruments a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MKSI - FREE

TheStreet Quant Ratings rates MKS Instruments as a buy. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and reasonable valuation levels. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full MKS Instruments Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Quantum Fuel Systems Technologies Worldwide (QTWW) - FREE Research Report

Timon Bradley J, who is Chief Financial Officer at Quantum Fuel Systems Technologies Worldwide, bought 10,000 shares at $1.95 on Dec. 15, 2014. Following this transaction, the Chief Financial Officer owned 89,512 shares meaning that the stake was boosted by 12.58% with the 10,000-share transaction.

Grutzner Paul Edward, who is Director at Quantum Fuel Systems Technologies Worldwide, bought 10,000 shares at $1.92 on Dec. 15, 2014. Following this transaction, the Director owned 35,437 shares meaning that the stake was boosted by 39.31% with the 10,000-share transaction.

Mcgaw Timothy Albert, who is Director at Quantum Fuel Systems Technologies Worldwide, bought 5,000 shares at $1.96 on Dec. 15, 2014. Following this transaction, the Director owned 11,000 shares meaning that the stake was boosted by 83.33% with the 5,000-share transaction.

The shares most recently traded at $2.16, up $0.20, or 9.26% since the insider transaction. Historical insider transactions for Quantum Fuel Systems Technologies Worldwide go as follows:

  • 4-Week # shares bought: 15,000
  • 12-Week # shares bought: 15,000
  • 24-Week # shares bought: 15,000

The average volume for Quantum Fuel Systems Technologies Worldwide has been 238,400 shares per day over the past 30 days. Quantum Fuel Systems Technologies Worldwide has a market cap of $42.8 million and is part of the consumer goods sector and automotive industry. Shares are down 76.28% year-to-date as of the close of trading on Friday.

Quantum Fuel Systems Technologies Worldwide, Inc. develops, produces, and sells natural gas fuel storage systems; and integrates vehicle system technologies in the United States, Germany, Canada, India, Spain, and Taiwan. Currently, there are 3 analysts who rate Quantum Fuel Systems Technologies Worldwide a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on QTWW - FREE

TheStreet Quant Ratings rates Quantum Fuel Systems Technologies Worldwide as a sell. The company's weaknesses can be seen in multiple areas, such as its poor profit margins, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full Quantum Fuel Systems Technologies Worldwide Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Endologix (ELGX) - FREE Research Report

Love Charles Steele, who is VP-Clinical Affairs at Endologix, sold 10,000 shares at $13.95 on Dec. 15, 2014. Following this transaction, the VP-Clinical Affairs owned 34,963 shares meaning that the stake was reduced by 22.24% with the 10,000-share transaction.

The shares most recently traded at $13.75, down $0.20, or 1.46% since the insider transaction. Historical insider transactions for Endologix go as follows:

  • 4-Week # shares bought: 2,000
  • 4-Week # shares sold: 3,500
  • 12-Week # shares bought: 27,000
  • 12-Week # shares sold: 3,500
  • 24-Week # shares bought: 27,000
  • 24-Week # shares sold: 3,500

The average volume for Endologix has been 680,900 shares per day over the past 30 days. Endologix has a market cap of $918.4 million and is part of the health care sector and health services industry. Shares are down 20.13% year-to-date as of the close of trading on Friday.

Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States, Europe, and rest of the world. Currently, there are 3 analysts who rate Endologix a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ELGX - FREE

TheStreet Quant Ratings rates Endologix as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Endologix Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null